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http://www.biomedcentral.com/1471-2407/14/119RESEARCH ARTICLE Open AccessDecreased expression of Yes-associated protein is
associated with outcome in the luminal A breast
cancer subgroup and with an impaired tamoxifen
response
Sophie Lehn1*, Nicholas P Tobin2, Andrew H Sims3, Olle Stål4, Karin Jirström5, Håkan Axelson6
and Göran Landberg7,8*Abstract
Background: Yes-associated protein (YAP1) is frequently reported to function as an oncogene in many types of
cancer, but in breast cancer results remain controversial. We set out to clarify the role of YAP1 in breast cancer by
examining gene and protein expression in subgroups of patient material and by downregulating YAP1 in vitro and
studying its role in response to the widely used anti-estrogen tamoxifen.
Methods: YAP1 protein intensity was scored as absent, weak, intermediate or strong in two primary breast cancer
cohorts (n = 144 and n = 564) and mRNA expression of YAP1 was evaluated in a gene expression dataset (n = 1107).
Recurrence-free survival was analysed using the log-rank test and Cox multivariate analysis was used to test for
independence. WST-1 assay was employed to measure cell viability and a luciferase ERE (estrogen responsive
element) construct was used to study the effect of tamoxifen, following downregulation of YAP1 using siRNAs.
Results: In the ER+ (Estrogen Receptor α positive) subgroup of the randomised cohort, YAP1 expression was
inversely correlated to histological grade and proliferation (p = 0.001 and p = 0.016, respectively) whereas in the
ER− (Estrogen Receptor α negative) subgroup YAP1 expression correlated positively to proliferation (p = 0.005).
Notably, low YAP1 mRNA was independently associated with decreased recurrence-free survival in the gene expression
dataset, specifically for the luminal A subgroup (p < 0.001) which includes low proliferating tumours of lower grade,
usually associated with a good prognosis. This subgroup specificity led us to hypothesize that YAP1 may be important
for response to endocrine therapies, such as tamoxifen, extensively used for luminal A breast cancers. In a tamoxifen
randomised patient material, absent YAP1 protein expression was associated with impaired tamoxifen response which
was significant upon interaction analysis (p = 0.042). YAP1 downregulation resulted in increased progesterone receptor
(PgR) expression and a delayed and weaker tamoxifen in support of the clinical data.
Conclusions: Decreased YAP1 expression is an independent prognostic factor for recurrence in the less aggressive
luminal A breast cancer subgroup, likely due to the decreased tamoxifen sensitivity conferred by YAP1 downregulation.
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The Yes-associated protein (YAP1) was discovered in
1994 as a binding partner of the SH3 domain of the Yes
proto-oncogene product [1]. Since then, a vast number
of publications describing the structure and function
of this transcriptional co-regulator have been published
(reviewed in [2]). The YAP1 protein contains several bind-
ing motifs which allow for protein-protein interactions;
for example the WW domain (present in either single or
dual form due to splicing events [3]) which can bind and
regulate proteins by interaction with a proline rich PPxY
motif. YAP1 also contains a TEAD binding domain neces-
sary for activation of the TEAD transcription factors,
which upon aberrant activation leads to increased cell
growth and proliferation, ultimately resulting in tissue
overgrowth [4-7]. In addition, the activation of TEAD by
YAP1 is reported to result in oncogenic transformation
of several cell types [8,9]. YAP1 has been reported to
bind and modulate the transcriptional activities of sev-
eral proteins such as Runx2, TEAD, p73, ErbB4, Smad7
and Smad1 [7,10-15].
To date, there are several reports on the function of
YAP1 as an oncogene in breast cancer models, but tumour
suppressive functions have also been reported. Overex-
pression of YAP1 leads to oncogenic transformation of
the immortalised MCF10A human breast cell line [16]
and the TEAD-interaction domain of a constitutively active
YAP1S127A mutant has been shown to promote tumour
growth and metastasis of murine mammary carcinoma cell
lines [17]. In addition, downregulation of YAP1 in the hu-
man breast cancer cell line MCF-7 resulted in decreased
cell proliferation and complete loss of tumour formation in
mice [18]. Similar results were obtained upon depletion of
YAP1 in the basal-like SW527 human breast cancer cell
line [19], altogether suggesting YAP1 to function as an
oncogene in breast cancer. Furthermore, YAP1 is now
widely recognized as one of the oncogenic drivers of 11q22
amplification in liver cancer [20,21] and in many other
cancer forms such as ovarian, lung and esophageal squa-
mous cell carcinoma, overexpression of YAP1 is correlated
to a worse outcome [22-24].
Despite these reports pointing to YAP1 as an onco-
gene, the role of YAP1 in breast cancer is far from clear.
Yuan and co-authors reported in 2008 that stable down-
regulation of YAP1 in breast cancer cell lines resulted in
protection of anoikis, promotion of anchorage-independent
growth and increased migration and invasion. YAP1 deple-
tion resulted in increased tumour growth in nude mice,
altogether suggesting a tumour suppressive function of
YAP1 in breast cancer [25]. The chromosomal location of
the YAP1 gene at 11q22 is also in favour of it functioning
as a tumour suppressor given the frequent loss of heterozy-
gosity (LOH) and deletions of this region in breast cancers
[26-30]. In addition, amplification of YAP1 in human breastcancer is infrequent [16] and YAP1 protein expression is
often decreased in primary breast cancer [25,31-33]. There-
fore, it might be challenging to translate in vitro findings of
YAP1 into a clinical setting. To our knowledge, there are
no reports concerning the expression of YAP1 and correla-
tions with outcome in subsets of breast cancer patients,
hence we set out to investigate and clarify the role of YAP1
in breast cancer.
In this study, we have examined the expression of YAP1
both on protein and gene expression level in a total of
1751 primary breast cancer samples with clinical follow-
up. We show that in ER+ breast cancer, decreased YAP1
expression is associated with more aggressive features
such as higher histological grade, increased proliferation
and lymph node positivity. In ER− breast cancer the re-
lationship is opposite and increased YAP1 expression
correlated to increased proliferation. Furthermore, low
YAP1 mRNA expression is independently associated with
a worse outcome in the luminal A molecular breast cancer
subgroup. We suggest this result relates to a decrease in
tamoxifen sensitivity which potentially results from the al-
tered levels of estrogen receptor (ER) and progesterone re-
ceptor (PgR) observed upon YAP1 downregulation in the
luminal breast cancer cell line T47D.
Methods
Patient data
Several patient cohorts were used in this study. The
‘screening cohort’ consisted of 144 women diagnosed
with primary invasive breast cancer at Malmö University
Hospital during the years of 2001 and 2002. Ethical per-
mission was obtained from the Lund University Regional
Ethics Board and written consent was not required. Me-
dian follow-up time for the patients was 5.75 years and
median age at diagnosis was 65 years (range 35-97 years).
All patients were treated following surgery. This cohort
was originally designed as a first-line breast cancer screen-
ing cohort for Human Protein Atlas antibodies and fur-
ther details of the material may be viewed in references
[34,35].
The ‘randomised cohort’ consisted of 564 premeno-
pausal patients presenting with invasive stage II breast
cancer who were enrolled in a randomised controlled
clinical trial, recruiting between the years of 1986 and
1991. The Lund University and Linköping University Re-
gional Ethics Boards approved the initial randomised study,
and there was no requirement for additional consent for
the present study. Tumour material was available from 500
patients. The primary aim of the trial was to determine the
effect of 2 years of tamoxifen treatment on recurrence-free
survival compared to no treatment and patients were in-
cluded regardless of ER status. Median follow-up time was
13.9 years and further details can be found in reference
[36]. Out of the 500 available tumours from the randomised
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sion. Analysis of the missing tumour cores showed a slight
correlation to PgR positivity (Spearman’s rho 0.105, p =
0.024), a lower NHG grade (Spearman’s rho -0.110, p =
0.013) and a low Ki-67 expression (Spearman’s rho -0.122,
p = 0.012). No differences were found in breast cancer re-
currences comparing the two groups.
For the gene expression analysis of 1107 primary breast
cancers, a meta-analysis of six comprised Affymetrix data-
sets was performed as previously described [37]. End-
points for datasets Chin et al., Pawitan et al. and Sotiriou
et al. was recurrence-free survival and for Desmedt et al.,
Ivshina et al. and Wang et al. datasets it was disease-free
survival. In this study, we have referred to all endpoints as
recurrence-free survival. The Affymetrix U133A probe set
ID used for YAP1 was 213342_at. The classification of
molecular breast cancer subgroups was made according to
the Norway/Stanford signature [37]. Further details of the
datasets included in the analysis can be found in refer-
ences [38-43].
The aCGH (array Comparative Genomic Hybridisation)
patient data set consisted of 171 patients with primary op-
erable breast cancer. The dataset is publicly available from
NCBI’s GEO under the series accession number GSE8757
and further details may be found in reference [44].
Tissue microarray, immunohistochemical staining and
scoring of YAP1 expression
Tumours from the screening and randomised cohorts
were assembled in tissue microarrays using a manual tis-
sue arrayer (MTA-1; BeecherInstruments, Inc., Sun Prairie,
WI). The pre-treatment process of deparaffinization, rehy-
dration and epitope retrieval of the 4 μm sections was
carried out using the PT Link module (Dako, Glostrup,
Denmark). Staining procedure with YAP1 antibody (1:25,
Cell Signaling Technology Inc., Danvers, MA, cat#4912)
was performed using the Autostainer Plus instrument
with the Envision Flex programme (Dako). The epitope
used for raising the YAP1 antibody includes amino acid
100 (personal communication, Cell Signaling Technology
Europe B.V.) and should therefore detect all to date
known isoforms of YAP1 [3]. YAP1 was scored as over-
all intensity as either absent, weak, intermediate or strong
by a research associate (SL) and a pathologist (GL). Ex-
pression of ER, Ki-67, cyclin D1 and amplification of
CCND1 (randomised cohort) had been scored previ-
ously in both the randomised and screening cohorts
[35,45,46].
Cell culture and transfection
The human breast cancer cell line T47D (ATCC, Int.,
Manassas, VA) was maintained in DMEM high glucose
medium supplemented with 10% fetal bovine serum
(FBS), 1 mM sodium pyruvate, 2 mM L-glutamine and1xPEST (streptomycin 90 μg/ml, penicillin 90 IU/ml).
Twenty-four hours before transfection, cells were seeded
in PEST-free media which was subsequently replaced
by PEST-free serum-free media and siRNA solution
(OptiMEM, Gibco, Lipofectamine 2000, Invitrogen Life
Technologies, Carlsbad, CA), yielding a final siRNA
concentration of 40 nM. For negative control, the
ON-TARGETplus Non-targeting control siRNA #2 (#D-
001810-02) was used and for targeting YAP1, two different
siRNAs were used; ON-TARGETplus YAP1 #7 (#J-012
200-07) and ON-TARGETplus YAP1 #8 (#J-012200-08)
(Dharmacon, Thermo Fisher Scientific Inc., Waltham,
MA). After five hours, transfection was discontinued by
replacement of medium to regular serum medium.
WST-1 cell viability assay
The effect of 17β-estradiol (E2) and 4-OH-tamoxifen
was determined by use of WST-1 assay. T47D cells were
seeded at a density of 400 000 cells in a 60 mm Ø cul-
ture dish (28.3 cm2) in PEST-free media and transfected
the following day as described. Forty-eight hours after
transfection, cells were re-seeded in phenol red-free DMEM
supplemented with 5% charcoal stripped serum in a 96-well
plate (5000 cells/well). After an additional 24 hours, cells
were incubated at 37°C in phenol red-free DMEM sup-
plemented with 1% charcoal stripped serum with either
control treatment (EtOH), 1 nM 17β-estradiol (E2)
(Sigma #E2758, Sigma-Aldrich Co, St. Louis, MO) or 1
nM E2 and increasing concentrations of 4-OH-tamoxifen
(10 nM, 100 nM and 1 μM) (Sigma #H7904, Sigma-
Aldrich Co), the active metabolite of tamoxifen, for 4 days.
WST-1 assay reagent (Roche Applied Science, Mannheim,
Germany) was subsequently added (10 μl) to each well
and cells were incubated for 4 hours at 37°C before the
absorbance of each well was measured at the wavelength
of 450 nm and reference wavelength of 690 nm, using a
scanning multiwell spectrophotometer (Synergy 2). Sta-
tistics were calculated using Student’s t-test assuming
unequal variances and the mean ± SD (standard devi-
ation) is presented. Each experiment was measured in
triplicate and repeated five times.
Western blotting and immunocytochemistry
For western blot analysis, cells were scraped in cold PBS
and lysed in ice-cold lysis buffer (0.1% Triton X-100, 0.5%
NaDOC, 0.1% SDS, 50 mM Tris-HCl pH 7, 150 mM
NaCl, 1 mM EDTA, 1 mM NaF) supplemented with pro-
tease inhibitor cocktail Complete Mini and phosphatase
inhibitor cocktail phosSTOP (Roche, Basel, Switzerland).
Cell extracts were kept on ice for 30 minutes and vortexed
every 10 min followed by centrifugation at 14 000 rpm for
30 min. Supernatants were subsequently collected and
protein concentration was determined using the BSA Pro-
tein Assay kit (Pierce, Rockford, IL). Twenty μg of protein
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onto nitrocellulose membranes (Hybond ECL, Amersham
Pharmacia Biotech, Buckinghamshire, UK). Primary anti-
bodies used included YAP1 (Cell Signaling Technology
Inc., Danvers, MA, cat#4912), cyclin D1 (clone SP4, Dako,
Glostrup, Denmark), cyclin A2 (H432, Santa Cruz Bio-
technology Inc., Dallas, TX, cat#sc-751), and actin (I-19,
Santa Cruz Biotechnology, Inc., Dallas, TX, cat#sc-1616).
For immunocytochemistry, cells were trypsinised and fixed
in 4% formaldehyde for 30 min followed by staining with
Meyer’s haematoxylin for 5 min. Cells were subsequently
centrifuged at 1400 rpm for 5 min and cell pellets were
resuspended in 70% ethanol over night. Cell pellets were
dehydrated in graded ethanol series, embedded in paraf-
fin and a cell pellet array was constructed and stained
using the following antibodies and dilutions: YAP1 (Cell
Signaling Technology Inc., Danvers, MA, 1:25, cat#4912),
ERα (clone 1D5, Dako, Glostrup, Denmark, 1:50, cat#M
7047) and PgR (clone 636, Dako, 1:1500, cat#M3569). The
experiment was repeated three times and one repre-
sentative experiment was quantified by automated image
analysis.
Luciferase assay
T47D cells were seeded in a 12-well plate at a density of
100 000 cells per well and transfected with siCtr, siYAP1 #7
or siYAP1 #8 as described. Forty-eight hours after siRNA
transfection, cells were re-transfected with 0.5 μg pGL2
luciferase reporter plasmid (pERE-luc) containing the
ER binding element ERE (Estrogen Response Element)
together with 0.2 μg of the Renilla expressing plasmid
pRL-TK, which served as an internal control. Five hours
later, transfection media was replaced by phenol red-
free DMEM, supplemented with 5% charcoal stripped
serum and PEST, and cells were kept in this media
24 hours prior to treatment initiation. Cells were subse-
quently treated with either 1 nM 17β-estradiol (E2)
(Sigma #E2758, Sigma-Aldrich Co, St. Louis, MO) or 1
nM E2 and 100 nM 4-hydroxi-tamoxifen (4-OH-tam)
combined (Sigma #H7904, Sigma-Aldrich Co). Ethanol
was used as control treatment, mimicking the amount
used for the E2 and E2 + 4-OH-tam wells. After 24 hours
of treatment, luciferase activity was measured using the
Dual-Luciferase® Reporter Assay System (Promega Cor-
poration, Madison, WI) and normalised to the internal
control. Three wells were included for each treatment in
every experiment (n = 3) and luciferase measurements were
made in triplicate.
Statistics
To examine statistical associations of YAP1 and clinical
and molecular parameters, the non-parametric Spearman’s
rank correlation coefficient test and Mann-Whitney U test
were employed. The p-values were not adjusted for multipletesting. Survival analysis was carried out using the Kaplan-
Meier method and recurrence-free survival was compared
by means of the log-rank test. The IBM SPSS software pro-
gram (version 20.0, IBM Corporation, Armonk, NY) was
used for calculation.
Statistical significance of differences in tamoxifen re-
sponse in cell viability experiments (WST-1) and luciferase
experiments were calculated using an unpaired two-tailed
student’s t-test assuming equal variances, unless stated
otherwise. Bars indicate the mean of at least three inde-
pendent experiments and error bars designate ± SD. Re-
sults were considered significant if p < 0.05.Results
YAP1 protein and mRNA expression in primary breast
tumour materials and correlations to clinicopathological
and molecular parameters
YAP1 overall protein intensity was scored as either ab-
sent, weak, intermediate or strong (Figure 1) in two dif-
ferent primary breast cancer cohorts (screening cohort,
n = 144 and randomised cohort, n = 500). YAP1 mRNA
expression was also explored using a large gene expres-
sion dataset consisting of six previously published pri-
mary breast cancer datasets totalling 1107 patients [37].
There were no correlations regarding YAP1 expression
and grade, lymph node status or tumour size when in-
cluding both ER+ and ER− patients in the analysis of the
two cohorts and the gene expression dataset (Tables 1, 2
and 3). We next divided our cohorts on the basis of es-
trogen receptor status. In the ER+ patient group of the
screening cohort, an inverse correlation between YAP1
expression and lymph node involvement was observed
(p = 0.022, Table 1) and in the ER+ subgroup of the rando-
mised cohort, YAP1 expression was negatively correlated
to proliferation (measured by Ki-67) and histological grade
(p = 0.016 and p = 0.001 respectively) (Table 2). In con-
trast, in the ER− subgroup of the randomised cohort, a
positive correlation between YAP1 expression and prolifer-
ation was observed illustrating the importance of perform-
ing subgroup analysis (p = 0.005) [see Additional file 1].
Furthermore, YAP1 expression was inversely linked to
ER and cyclin D1 expression in all three patient cohorts.
When dividing the materials according to ER status,
the inverse correlation between YAP1 and cyclin D1
only remained in the ER+ subgroups (Tables 1, 2 and 3,
Additional files 1 and 2). In the gene expression dataset,
YAP1 mRNA quartiles were positively correlated to tumour
size in the ER− subgroup (p = 0.037) [see Additional file 2].
Taken together, in ER+ tumours low YAP1 expression
is linked to more clinically aggressive features including
grade and proliferation. In ER− tumours the relationship
is reversed and high YAP1 expression was linked to more
aggressive features.
Figure 1 YAP1 staining in primary breast cancers. YAP1 overall intensity was scored as absent, weak, intermediate or strong. Scale bar = 50 μm.
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correlated in patient materials
The YAP1 gene is located at 11q22, a region often de-
leted upon amplification of the 11q13 region harbouring
the known oncogene cyclin D1 gene (CCND1), which is
amplified in 8-15% of all breast cancers and associated
with a worse prognosis [47-49]. The inverse correlation
seen between YAP1 and cyclin D1 protein and mRNA
expression could be due to a recurring chromosomal re-
arrangement, resulting in overexpressed cyclin D1 (follow-
ing amplification) and decreased YAP1 protein expression
(following deletion). CCND1 amplification had previously
been assessed in the randomised cohort (for further de-
tails, see ref [46]) and 9/14 ER+ patients (64%) with ab-
sent YAP1 expression also had amplification of CCND1
(Table 2). However, when removing the CCND1 amplified
cases from the analysis, the inverse correlation between
YAP1 and cyclin D1 protein expression in the ER+ sub-
group remained (Spearman’s rho -0.206, p = 0.030) indicat-
ing additional mechanisms for maintaining the negative
relationship. This was despite the fact that CCND1 ampli-
fied cases were associated with a stronger cyclin D1 ex-
pression in this material (data not shown).
The inverse correlation of CCND1 and YAP1 was further
examined in an aCGH dataset. Amplification of CCND1
was frequently associated with loss of YAP1 [see Additional
file 3]. Nonetheless, amplification of CCND1 was not a
prerequisite for YAP1 gene loss, as there were several tu-
mours with low YAP1 copy number where increasedCCND1 copy numbers were not present [Additional file 3b,
lower panel].
To summarise, CCND1 amplification is associated with
YAP1 gene loss but the negative association between the
proteins is not entirely dependent on chromosomal rear-
rangements, as the correlation remains after removing
cases of CCND1 amplification. Furthermore, YAP1 gene
loss may occur independently of CCND1 amplification.
YAP1 mRNA expression holds independent prognostic value
In order to investigate the influence of YAP1 expression
on disease outcome, survival analyses were performed.
In the screening cohort, YAP1 expression was not associ-
ated with recurrence-free survival [see Additional file 4].
The gene expression dataset was analysed for recurrence
using the median of YAP1 mRNA expression as a cut-
off to define groups of high or low YAP1 expression
(Figure 2a). Low YAP1 mRNA expression was corre-
lated to a decreased recurrence-free survival and YAP1
mRNA proved to be an independent prognostic factor
after adjustment for known prognostic factors such as
grade, tumour size and lymph node involvement [see
Additional file 5].
As correlations in the screening and randomised patient
cohorts implied that YAP1 behaves differently depending
on the tumours’ expression of ER, recurrence-free survival
was analysed in ER+ and ER− subgroups of the gene ex-
pression dataset (Figure 2b and c). In the ER+ subgroup,
the two lower quartiles correlated to a shorter recurrence-
Table 1 Correlations of YAP1 protein expression and clinical and molecular parameters of the screening cohort (n=144)
All patients, n=144 ER+ patients, n=125
YAP1 intensity, n=117 YAP1 intensity, n=99
Absent Weak Intermediate Strong Absent Weak Intermediate Strong
n (%) n (%) n (%) n (%) p-value n (%) n (%) n (%) n (%) p-value
Variable 4 (3) 52 (44) 38 (33) 23 (20) 4 (4) 46 (47) 35 (35) 14 (14)
NHG
I 0 3 (6) 6 (16) 2 (9) 0 3 (7) 6 (17) 2 (14)
II 2 (50) 26 (50) 19 (50) 9 (41) 2 (50) 25 (54) 19 (54) 9 (64)
III 2 (50) 23 (44) 13 (34) 11 (50) 0.646a 2 (50) 18 (39) 10 (29) 3 (21) 0.060a
Lymph node status
Negative 1 (25) 26 (52) 22 (65) 12 (63) 1 (25) 23 (51) 20 (63) 10 (83)
Positive 3 (75) 24 (48) 12 (35) 7 (37) 0.128b 3 (75) 22 (49) 12 (37) 2 (17) 0.022b
Tumour size
<20 mm 0 26 (50) 18 (47) 9 (41) 0 24 (55) 18 (51) 8 (57)
≥20 mm 4 (100) 26 (50) 20 (53) 13 (59) 0.995b 4 (100) 22 (45) 17 (49) 6 (43) 0.347b
ERα
<10% 0 6 (12) 3 (8) 8 (36) - - - -
≥10% 4 (100) 46 (88) 35 (92) 14 (64) 0.030b - - - -
PgR
<10% 1 (25) 17 (33) 9 (24) 14 (64) 1 (25) 12 (26) 6 (17) 6 (43)
≥10% 3 (75) 35 (67) 29 (76) 8 (36) 0.084b 3 (75) 34 (74) 29 (83) 8 (57) 0.691b
Ki-67 fraction (%)
0-10 0 0 3 (8) 2 (10) 0 0 3 (9) 2 (15)
11-25 2 (67) 20 (44) 18 (49) 7 (33) 2 (67) 18 (45) 18 (53) 6 (46)
26-100 1 (33) 25 (56) 16 (43) 12 (57) 0.626a 1 (33) 22 (55) 13 (38) 5 (39) 0.091a
Cyclin D1 intensity
Negative/Low 0 19 (51) 20 (67) 12 (86) 0 17 (53) 17 (63) 6 (75)
Moderate/High 4 (100) 18 (49) 10 (33) 2 (14) 0.002b 4 (100) 15 (47) 10 (37) 2 (25) 0.040b
NHG=Nottingham histological grade, ER=estrogen receptor, PgR=progesterone receptor.
aSpearman´s rank correlation.
bMann-Whitney U test.
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was the opposite. Quartiles 2, 3 and 4 were in the bottom
of the graph whereas quartile 1 (holding the tumours of
lowest YAP1 mRNA expression) demonstrated a remark-
ably better outcome after 5 years of follow-up, although the
trend was not persistent. These results are well in line with
the correlations in Tables 1, 2 and 3, implying a contrasting
function of YAP1 in breast cancer subgroups.
Low YAP1 mRNA expression is specifically correlated to
worse outcome in the luminal A breast cancer subgroup
We further explored if YAP1 mRNA had different sig-
nificance in regards to outcome in breast cancer mo-
lecular subgroups. Strikingly, low YAP1 mRNA was only
of importance in the luminal A subtype and of no import-
ance in the remaining four subtypes (luminal B, HER2,
basal-like and normal-like) when dividing the datasetaccordingly (Figure 2d-h). Subgroup analysis of YAP1
mRNA expression showed that expression was signifi-
cantly higher in the normal-like and basal-like subgroups
compared to the luminal A and B subgroups. However, no
statistical difference was found between luminal A and B
subgroups [see Additional file 6].
Due to the frequent deletion of the 11q22 chromo-
somal region, several genes in close proximity to YAP1
were tested for correlation and outcome in the gene ex-
pression dataset [see Additional file 7]. However, YAP1
was the only factor which remained significant of out-
come in the multivariate analysis for the luminal A sub-
group [see Additional file 8].
In conclusion, decreased YAP1 mRNA expression is a
prognostic factor in the luminal A subgroup, independ-
ent of a selection of proximal 11q22 genes, cyclin D1 or
established prognostic factors.
Table 2 Correlations of YAP1 protein expression and clinical and molecular parameters of the randomised cohort (n=500)
All patients, n= 500 ER+ patients, n=324
YAP1 intensity, n=324 YAP1 intensity, n=213
Absent Weak Intermediate Strong p-value Absent Weak Intermediate Strong p-value
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Variable 28 (9) 130 (40) 128 (39) 38 (12) 21 (10) 95 (45) 79 (37) 18 (8)
NHG
I 0 10 (8) 11 (9) 5 (13) 0 10 (11) 11 (14) 5 (28)
II 13 (48) 55 (44) 56 (45) 10 (27) 12 (57) 48 (50) 51 (65) 9 (50)
III 14 (52) 60 (48) 57 (46) 22 (60) 0.932a 9 (43) 37 (39) 16 (21) 4 (22) 0.001a
Lymph node status
Negative 7 (25) 35 (27) 34 (27) 15 (41) 5 (24) 25 (26) 19 (24) 5 (29)
Positive 21 (75) 94 (73) 94 (73) 22 (59) 0.285b 16 (76) 70 (74) 60 (76) 12 (71) 0.971b
Tumour size
<20 mm 12 (44) 43 (33) 46 (36) 13 (34) 10 (50) 35 (37) 33 (42) 6 (33)
≥20 mm 15 (56) 87 (67) 82 (64) 25 (66) 0.815b 10 (50) 60 (63) 46 (58) 12 (67) 0.757b
ERα
<10% 4 (16) 33 (26) 46 (37) 20 (53) - - - -
≥10% 21 (84) 95 (74) 79 (63) 18 (47) <0.001b - - - -
PgR
<10% 6 (24) 35 (29) 47 (39) 20 (56) 1 (5) 6 (7) 4 (5) 0
≥10% 19 (76) 86 (71) 75 (61) 16 (44) 0.002b 18 (95) 84 (93) 73 (95) 16 (100) 0.464b
Ki-67 fraction (%)
0-10 12 (48) 48 (40) 53 (45) 10 (29) 9 (47) 37 (42) 47 (64) 9 (56)
11-25 7 (28) 38 (32) 34 (29) 7 (20) 6 (32) 30 (34) 20 (27) 3 (19)
26-100 6 (24) 34 (28) 31 (26) 18 (51) 0.198a 4 (21) 21 (24) 6 (8) 4 (25) 0.016a
Cyclin D1 intensity
absent/weak 8 (31) 67 (53) 81 (67) 29 (76) 3 (14) 39 (42) 40 (51) 9 (50)
intermediate/strong 18 (69) 59 (47) 40 (33) 9 (24) <0.001b 18 (86) 54 (58) 38 (49) 9 (50) 0.010b
CCND1 amplification
No 8 (44) 69 (84) 75 (89) 24 (96) 5 (36) 48 (80) 47 (84) 12 (92)
Yes 10 (56) 13 (16) 9 (11) 1 (4) <0.001b 9 (64) 12 (20) 9 (16) 1 (8) 0.003b
NHG=Nottingham histological grade, ERα=estrogen receptor, PgR=progesterone receptor.
aSpearman´s rank correlation.
bMann-Whitney U test.
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http://www.biomedcentral.com/1471-2407/14/119Absence of YAP1 protein expression in primary breast
tumours is linked to an impaired tamoxifen response
The prominent effect of decreased YAP1 mRNA in the
luminal A subtype led us to hypothesize that YAP1
could be important for the response to endocrine ther-
apies. The majority of luminal A classified tumours are
ER+ and hence treated with some variant of endocrine
targeting treatment such as tamoxifen. To study the
possible effect of YAP1 loss on tamoxifen response,
recurrence-free survival was analysed in the randomised
cohort, as this patient material originates from a clinical
trial evaluating tamoxifen response in a randomised set-
ting. Significance of YAP1 expression was initially analysed
in ER+ and ER− subgroups, as molecular subgroup datawas not available for this cohort. Figure 3a, which included
both treated and untreated ER+ patients, showed signifi-
cantly decreased recurrence-free survival when YAP1 ex-
pression was absent. In the ER− subgroup, both absent and
strong YAP1 expression correlated to a worse outcome
(Figure 3b). ER+ patients were then divided according to
whether they received tamoxifen or control treatment
(Figure 3c and d). YAP1 expression was not correlated
to outcome in the untreated ER+ patient subgroup
whereas there were significant differences in outcome in
the tamoxifen treated ER+ subgroup. Figure 3e and f
specifically address the tamoxifen response. ER+ patients
with tumours of YAP1 expression scored as either weak,
intermediate or strong (score 1-3) did significantly better
Table 3 Correlations of YAP1 mRNA expression and clinical and molecular parameters of the gene expression
dataset (n=1107)
All patients, n=1107 ER+ patients, n=700
YAP1 mRNA Quartiles YAP1 mRNA Quartiles
Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Variable n=277 (%) n=276 (%) n=277 (%) n=277 (%) p-value n=175 (%) n=175 (%) n=175 (%) n=175 (%) p-value
NHG
I 29 (15) 43 (24) 46 (24) 49 (24) 17 (15) 34 (31) 33 (28) 38 (30)
II 94 (47) 79 (43) 77 (40) 80 (38) 60 (51) 48 (44) 54 (46) 48 (37)
III 77 (38) 61 (33) 69 (36) 80 (38) 0.355a 40 (34) 27 (25) 31 (26) 42 (33) 0.165a
Lymph node status
Negative 187 (81) 207 (87) 194 (80) 192 (85) 138 (80) 155 (89) 139 (81) 138 (79)
Positive 44 (19) 31 (13) 47 (20) 35 (15) 0.715b 34 (20) 20 (11) 32 (19) 36 (21) 0.433b
Tumour size
<20 mm 78 (48) 85 (54) 93 (54) 82 (48) 55 (45) 59 (52) 72 (59) 76 (56)
≥20 mm 86 (52) 72 (46) 78 (46) 88 (52) 0.917b 66 (55) 54 (48) 50 (41) 59 (44) 0.056b
ERα
<10% 44 (19) 57 (24) 56 (23) 82 (36) - - - -
≥10% 188 (81) 180 (76) 187 (77) 145 (64) <0.001b - - - -
PgR Quartiles
Q1 66 (24) 62 (22) 60 (22) 89 (32) 51 (29) 45 (26) 36 (21) 43 (25)
Q2 82 (30) 76 (28) 60 (22) 59 (21) 49 (28) 48 (27) 41 (23) 37 (21)
Q3 76 (27) 70 (25) 71 (25) 60 (22) 40 (23) 43 (25) 48 (27) 44 (25)
Q4 53 (19) 68 (25) 86 (31) 69 (25) 0.836a 35 (20) 39 (22) 50 (29) 51 (29) 0.011a
Cyclin D1 Quartiles
Q1 57 (20) 73 (26) 66 (24) 81 (29) 31 (18) 45 (26) 51 (29) 48 (27)
Q2 41 (15) 63 (23) 87 (31) 85 (31) 26 (15) 47 (27) 53 (30) 49 (28)
Q3 69 (25) 69 (25) 78 (28) 61 (22) 47 (27) 33 (19) 44 (25) 51 (29)
Q4 110 (40) 71 (26) 46 (17) 50 (18) <0.001a 71 (41) 50 (28) 27 (16) 27 (16) <0.001a
NHG=Nottingham Histological Grade, ER=Estrogen receptor, PgR=Progesterone receptor.
aSpearman´s rank correlation.
bMann–Whitney U test.
Lehn et al. BMC Cancer 2014, 14:119 Page 8 of 16
http://www.biomedcentral.com/1471-2407/14/119when treated with tamoxifen compared to no treatment.
In the group of patients with tumours of absent YAP1
expression (score 0), there was no difference in outcome
between the control and tamoxifen group. A multivari-
ate interaction analysis further demonstrated a statisti-
cally significant association between absent YAP1 and
an impaired response to tamoxifen (p = 0.042, Table 4).
These results suggest YAP1 as a predictive marker for
tamoxifen response.
YAP1 downregulation in the luminal cell line T47D results
in a weaker tamoxifen response
The T47D cell line was chosen to further investigate the
role of YAP1 in tamoxifen response due to its relatively
high expression of YAP1 compared to other luminal cell
lines such as MCF-7, and also since proliferation in this cell
line is not significantly affected by YAP1 downregulation[see Additional file 9] [18,50]. YAP1 was transiently down-
regulated followed by treatment with 17β-estradiol (E2) or
E2 and increasing concentrations of 4-OH-tamoxifen. Cell
viability was subsequently evaluated by means of WST-1
assay. YAP1 protein levels were efficiently downregulated
and maintained at a depleted level even after 4 days of
treatment (Figure 4a). There were no notable differences in
the expression of the cell cycle proteins cyclin D1 and cyc-
lin A2 when YAP1 was downregulated, although a slight
decrease in cyclin A2 was noted in the EtOH control
treated cells following YAP1 silencing (Figure 4a), com-
pared to siCtr cells. To evaluate tamoxifen response, cell
viability fold change was calculated comparing different
concentrations of tamoxifen to estrogen stimulation, within
a cell population treated with a specific siRNA (Figure 4b).
Both siCtr and siYAP1 #7 demonstrated significant changes
in cell viability upon addition of 10-7 M 4-OH-tamoxifen,
Figure 2 YAP1 mRNA predicts outcome in molecular subgroups of primary breast cancer. (a) YAP1 mRNA expression was dichotomised
at the median value to generate high and low YAP1 expressing groups. Low YAP1 mRNA correlates to a decreased recurrence-free survival in the
entire dataset. (b) YAP1 mRNA quartiles of the ER+ subgroup (n = 700) correlates to a decreased recurrence-free survival whereas the trend in
the (c) ER− subgroup (n = 239) is opposite but not significant. (d-h) Survival analyses in breast cancer molecular subgroups. Low YAP1 mRNA
is associated with decreased recurrence-free survival in the luminal A but not luminal B, HER2, basal or normal-like subgroups. Q = quartile,
RFS = recurrence-free survival.
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http://www.biomedcentral.com/1471-2407/14/119whereas for siYAP1 #8, 4-OH-tamoxifen had no significant
effect until the concentration of 10-6 M was reached. SiCtr
treated cells responded significantly better to rising concen-
trations of 4-OH-tamoxifen (p = 0.006) whereas siYAP #7
and #8 showed no such dependence (p = 0.09 and p = 0.10,
respectively).
To more specifically address the activity of ER, a lucif-
erase assay measuring the activation of the estrogen re-
sponse element (ERE) was employed. T47D cells were first
transfected with siCtr, siYAP1 #7 or siYAP1 #8 followed by
a pERE-luciferase construct transfection, and treated with
E2 or a combination of E2 and 4-OH-tamoxifen for
24 hours (Figure 4c). Downregulation of YAP1 resulted in a
less efficient tamoxifen-induced inhibition of ER activity,where siCtr cells showed a 4.52 fold decrease compared to
only 3.33 and 3.79 for siYAP1 #7 and #8 cells, respectively.
To summarise, although a response to tamoxifen was
still measurable, downregulation of YAP1 in the T47D
cell line resulted in a later and less efficient tamoxifen
response.
Downregulation of YAP1 results in increased ER and PgR
protein levels
As ER and PgR protein expression are of great import-
ance in predicting response to tamoxifen [51], T47D cell
pellets (siCtr, siYAP1 #7 and #8) treated with EtOH, E2
or E2 and 4-OH-tamoxifen combined were examined for
ER and PgR protein expression by immunocytochemistry
Figure 3 Absence of YAP1 protein expression is associated with tamoxifen resistance in the randomised patient cohort. (a) Kaplan-Meier
analysis of all ER+ patients, both treated (tamoxifen) and untreated. Absent YAP1 expression is correlated to a decreased recurrence-free survival. (b) In
the ER− subgroup both absent and strong YAP1 expression correlated to a worse outcome. (c) Analysis of the untreated patient cohort of ER+ patients
indicates no prognostic value of YAP1. (d) Analysis of the tamoxifen treated patient cohort of ER+ patients suggests predictive value of absent YAP1.
(e) ER+ patients with tumours scored as weak, intermediate or strong YAP1 expression do significantly better when treated with tamoxifen compared
to the untreated control group whereas (f) ER+ patients with YAP1 scored as absent do not benefit from tamoxifen. RFS = recurrence-free survival.
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http://www.biomedcentral.com/1471-2407/14/119(Figure 5). The knockdown of YAP1 was not 100% com-
plete but the increase of YAP1 protein expression seen in
siCtr cells upon E2 stimulation was effectively inhibited in
siYAP#7 and #8 cells. Interestingly, siYAP1 #7 and #8 dis-
played a strong overall increase in PgR intensity, even inTable 4 The difference in treatment response between patien
multivariate Cox proportional hazards regression analysis for
breast cancer patients*
Variable Category
YAP1 expression Weak, intermediate or strong
Absent
Treatment Control
Tamoxifen
Interaction variable† Tamoxifen x YAP1 expression
*Other factors included in the analysis are tumour grade (NHG I + II vs. III), nodal sta
†Interaction variable states if there is a difference in the treatment response in relat
HR = Hazard ratio, CI = Confidence interval, NHG = Nottingham histological grade.control treated (EtOH) cells. The decrease of PgR in 4-
OH-tamoxifen treated siCtr cells was not as evident in
siYAP1 #7 and #8 cells. As previously reported, ER is
downregulated upon E2 treatment, an effect antagonised
by tamoxifen which stabilises ER [52]. Although this effectt groups of different YAP1 expression is significant: A
YAP expression and treatment interaction based on ER+
Recurrence-free survival
HR 95% CI P value
1.00
1.42 0.56 to 3.59 0.456
1.00
0.42 0.26 to 0.68 <0.001
3.51 1.05 to 11.75 0.042
tus (negative vs. positive) and tumor size (≤ 20 mm vs. >20 mm).
ion to YAP1 expression.
Figure 4 Downregulation of YAP1 results in a weaker tamoxifen response in the T47D cell line. T47D cells were transfected with siCtr,
siYAP1 #7 or siYAP1 #8 and 48 h later medium was changed to phenol red-free DMEM supplemented with 5% charcoal stripped serum. Twenty-four
hours later, the indicated treatment was added and after 4 days, cells were analysed for (a) YAP1, cyclin D1 and cyclin A2 protein expression by western
blot (b) viability by WST-1 assay. Treatment of T47D results in a significant tamoxifen response for siCtr and siYAP1 #7 at 10-7 M 4-OH-tam whereas
siYAP1 #8 was not significantly affected until 10-6 M 4-OH-tam. SiCtr cells respond significantly better to increasing concentrations of 4-OH-
tam (**p = 0.006). No significant changes in response was observed when increasing 4-OH-tam in siYAP1 downregulated cells (siYAP1 #7,
p = 0.09 and siYAP1 #8, p = 0.10). All values were related to EtOH treated siCtr cells. (c) T47D cells were transfected with siCtr, siYAP1 #7 or
siYAP1 #8 followed by transfection with pERE-luc and pRL-TK as internal control. The mean value ± SD is indicated and fold decrease upon
tamoxifen treatment (compared to E2 activation) is shown below the graph. P-values were calculated using paired student’s t-test (two-sided).
*p < 0.05, **p < 0.01, ***p < 0.001. 4-OH-tam = 4-hydroxi-tamoxifen, E2 = 17β-estradiol, n.s. = no significance.
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http://www.biomedcentral.com/1471-2407/14/119was seen in all siRNA treatments, the expression of ER
was higher overall in siYAP #7 and #8. Taken together,
downregulation of YAP1 increased the level of hormone
receptors, indicating deregulation of hormone receptor
signalling when YAP1 is decreased.
Discussion
In this study, we have shown that decreased mRNA levels
of YAP1 independently predict outcome in ER+ and more
specifically, luminal A breast cancers. This subgroup speci-
ficity led us to hypothesize that YAP1 is of importance in
the response to endocrine treatments used to target the
estrogen receptor, such as the widely used anti-estrogen
tamoxifen. By examining a premenopausal primary breast
tumour material randomised to either tamoxifen or controltreatment, we found that absent YAP1 protein expression
was associated with impaired tamoxifen response. Although
effects were small, downregulation of YAP1 in a luminal
breast cancer cell line resulted in a weaker tamoxifen re-
sponse as measured by cell viability and activity of the es-
trogen receptor. In addition, silencing of YAP1 resulted in
increased protein levels of ER and PgR, indicating increased
signalling and deregulation of the ER pathway, a possible
mechanism for the weaker tamoxifen response in this
cell line.
The role of YAP1 in breast cancer is at present a matter
of debate. By placing the protein in the context of estrogen
receptor positive or negative disease, some reported results
which appear contradictory may be explained. In 2006,
Overholtzer et al. published a report on the oncogenic
Figure 5 ER and PgR protein levels increase upon YAP1 downregulation. (a) Immunocytochemical stainings of the T47D cell line. Cells were
transfected with the indicated siRNA and 48 hours later, medium was changed to phenol red-free DMEM supplemented with 5% charcoal stripped serum
in which cells were grown for 24 hours. Subsequently, 10-9 M E2 or 10-9 M E2 combined with 10-7 M 4-OH-tam was added and 4 days later cells were
harvested, fixed and stained using the indicated antibody. (b) Quantification by automated image analysis of stained cell pellets. Bars represent the
percentage of positive pixels identified in the image analysis. ER = estrogen receptor α, PgR = progesterone receptor, 4-OH-tam= 4-hydroxi-tamoxifen,
E2 = 17β-estradiol.
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http://www.biomedcentral.com/1471-2407/14/119properties of YAP1, which had been identified through a
screen for copy number changes in mouse mammary tu-
mours. Interestingly, the genetic background used for
screening was the Brca1/Trp-53 which in the majority of
cases gives rise to ER− mammary tumours of high grade
[53]. The normal cell line subsequently used for transform-
ation experiments was MCF-10A, reported to be ER− [54],
altogether suggesting a possible function of YAP1 as an
oncogene in ER− breast cancer. This is in support of our
results where strong YAP1 expression was associated with
increased proliferation in ER− tumours [see Additionalfile 1]. Furthermore, YAP1 was recently reported to func-
tion as an oncogene by promoting proliferation and sur-
vival of breast cancer cells by binding and stabilising the
KLF5 (Kruppel-like factor 5) transcription factor through
its PPxY motif [19]. KLF5 and YAP1 were reported to be
predominately expressed in ER− cell lines and all experi-
mental data was obtained from ER− breast cancer cell lines.
Activation of YAP1 in the ER− cell line SUM159 [55] medi-
ated by LIFR (leukemia inhibitory factor receptor) repres-
sion resulted in substantial lung metastases in nude mice,
again suggesting an oncogenic role of YAP1 in ER− breast
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http://www.biomedcentral.com/1471-2407/14/119cancer [56]. The fundamental differences on the transcrip-
tomic level of ER+ and ER− breast cancers is long estab-
lished [57], and our results indicate that subgroup analysis
is critical for the translational understanding of YAP1 in
breast disease. There are however also reports where YAP1
show oncogenic features in ER+ breast cancer models. For
example, stable knockdown of YAP1 in the ER+ human
breast cancer cell line MCF-7 resulted in complete loss of
tumour formation in BALB/c nude mice [18]. As YAP1
knockdown significantly decreased proliferation in MCF-7
cells, the negative result in tumour formation was perhaps
expected. In the randomised breast cancer material studied
here, decreased YAP1 expression was associated with in-
creased proliferation in ER+ breast cancers (Table 2), indi-
cating a discrepancy between the ER+ cell line model and
primary breast cancer data. The effects of protein downreg-
ulation in cell line models are usually assessed after days or
weeks, whereas primary tumours evolve during a period of
years. As YAP1 loss is proposed to be an early event in
breast cancer [25], YAP1 downregulation in cell lines such
as MCF-7 might have to be assessed at much later time
points in order to better correlate findings between primary
tumour data and cell lines. The microenvironment might
also constitute a critical parameter for understanding and
modelling YAP1 in breast cancer, and stable downregula-
tion of YAP1 in MCF-7 has been reported to result in in-
creased invasion in a matrigel transwell assay [25].
The notion of YAP1 functioning as a tumour suppres-
sor in breast cancer was first proposed by Yuan et al. in
2008 [25]. The 11q22 region where the YAP1 gene is lo-
cated is a frequent site of LOH (loss of heterozygosity)
in breast cancer [26-30] and Yuan et al. reported that
half of tumours negative for YAP1 staining also had spe-
cific LOH at the YAP1 gene locus. This indicates 11q22
deletions as part of the explanation to the recurrent de-
creased YAP1 protein levels in breast cancer, but also
supports the possibility of additional unknown mecha-
nisms contributing to YAP1 protein loss in breast can-
cer [25,31-33]. Furthermore, downregulation of YAP1
was shown to increase anoikis, migration and invasion,
altogether suggesting a tumour suppressive function for
YAP1 [25]. In our study, YAP1 expression was not in-
formative of outcome in the untreated ER+ subgroup of
the randomised cohort (Figure 3c) which might be ex-
pected if YAP1 had had true tumour suppressive prop-
erties. In the ER+ tamoxifen treated subgroup, there
were great differences in outcome depending on YAP1
expression (Figure 3d). Altogether, these results suggest
YAP1 to function as a treatment predictive factor in ER+
breast cancer, rather than a prognostic factor for the nat-
ural disease progression.
CCND1 amplification has previously been linked to a
poor tamoxifen response, however cyclin D1 protein ex-
pression could not predict response as efficiently as theamplification event [46]. This indicates additional events
affecting tamoxifen response associated with CCND1 amp-
lification. Co-amplification of other 11q13 genes is most
likely of importance, but deletions of distal 11q might also
contribute to tamoxifen resistance [58] and YAP1 is a likely
candidate considering the data presented herein. CCND1
amplified breast tumours have been reported to display
loss of the distal part of 11q in 70% of cases [59]. However,
the inverse correlation of cyclin D1 and YAP1 protein ex-
pression observed in the randomised tumour material
remained after removing the CCND1 amplified cases from
the analysis, indicating additional functions for maintaining
the negative relationship between the two proteins. Also, it
has been reported that loss of distal 11q may occur in-
dependently of 11q13 amplification [26] as shown in
[Additional file 3b] where YAP1 loss is present inde-
pendently of CCND1 amplification in several cases (red
arrows). Hence, our results suggest that loss of YAP1 may
confer aggressiveness in ER+ breast cancers independently
of the established oncogenic CCND1 amplification.
The differences in correlations between the two pa-
tient cohorts might partly be explained by dissimilarities
of the cohorts. The randomised patient cohort only in-
cluded premenopausal patients with stage II breast can-
cer which renders this a more defined group compared
to the screening cohort, where all patients with breast
tumours defined as invasive was included. In the much
smaller screening cohort, only four patients were assessed
to have absent YAP1 protein expression, challenging the
analysis since the complete loss of YAP1 appeared to be
the conclusive factor on protein level. The conformity in
treatment of the randomised cohort was further valuable
for investigating the effect of YAP1 on tamoxifen re-
sponse, whereas patients in the screening cohort were
treated according to guidelines.
YAP1 has previously been reported to be able to en-
hance the hormone dependent activation of ER and PgR
by acting as a coactivator through direct interaction with
WW domain binding protein-2, WBP-2 [60]. The coactiva-
tion function of YAP1 was shown to be strictly dependent
on the presence of WBP-2 which binds the estrogen recep-
tor in a complex with E6-AP (E6-associated protein) upon
E2 stimulation. From this perspective, downregulation of
YAP1 would potentially lead to a decreased activation of
ER in our experimental setting. Instead, the trend is an
increase in ER signalling upon YAP1 downregulation il-
lustrated by the increase in PgR protein levels in Figure 5,
given that PgR is a known target gene of E2 signalling
[61]. Interestingly, stabilisation of PgR has previously been
shown to be important in Brca1-mediated tumorigenesis
[62,63]. Also, no effect was observed on the E2 dependent
activation of the Estrogen Responsive Element (ERE) upon
depletion of YAP1. If any effect, the activity of the ERE is
increased (siYAP1 #8, Figure 4c).
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http://www.biomedcentral.com/1471-2407/14/119In vitro experiments downregulating YAP1 in the lu-
minal A classified T47D cell line resulted in a weaker re-
sponse to tamoxifen as measured by cell viability. There
were several reasons for choosing the T47D cell line for
the modelling of tamoxifen response. First, T47D cells
have a higher gene and protein expression of YAP1 com-
pared to other luminal breast cancer cell lines such as
MCF-7, making the T47D cell line more suitable for
YAP1 downregulating experiments [see Additional file 9c]
[18,50]. Second, T47D cells are not as reliant on YAP1 for
proliferation as MCF-7 cells [see Additional file 9a and b]
which also favours the selection of the T47D cell line. In
Figure 4b, the two siRNAs targeting YAP1 show some-
what diverging results where siYAP1 #7 resulted in a
significant tamoxifen response already at treatment of
10-7 M 4-OH-tamoxifen, but siYAP1 #8 did not reach
significance until a 10-fold higher tamoxifen concentra-
tion was used. Also, increasing concentrations of 4-OH-
tamoxifen in siCtr-treated cells resulted in a more effective
inhibition of cell viability. This effect could not be ob-
served upon YAP1 depletion, in support of YAP1 being
important for the 4-OH-tamoxifen effect. The general
negative effect of YAP1 downregulation on cell viability
somewhat complicates the interpretation of the result,
however when measuring the specific activity of the estro-
gen response element upon E2 stimulation with or with-
out YAP1, similar results were obtained. The fold decrease
resulting from 4-OH-tamoxifen inhibition was less prom-
inent when YAP1 was downregulated (siYAP1 3.33-3.79
vs. siCtr 4.52), indicating a role for YAP1 in mediating in-
hibition of ERE activity. The small but significant effect
implies additional mechanisms contributing to YAP1’s role
in tamoxifen resistance; for example, the known estrogen
target gene cyclin D1 does not have an ERE promoter
element, instead a cAMP response like element is sug-
gested to be critical in mediating the transcriptional activa-
tion of the cyclin D1 gene upon E2 stimulation [64].
Possibly, measurement of cAMP response like element
activation in a similar setting as described would yield
additional support for the involvement of YAP1 in ER-
mediated transcription.
Conclusion
By analysing YAP1 mRNA and protein expression in a
large number of primary breast tumours, we show that
increased YAP1 is associated with more aggressive tu-
mours in ER− breast tumours whereas in ER+ tumours,
decreased YAP1 expression correlates to aggressiveness.
These results clearly indicate the necessity of analysing
ER+ and ER− breast tumours separately regarding YAP1
expression. Furthermore, low YAP1 mRNA expression
was significantly associated with a decreased recurrence-
free survival in the luminal A breast cancer subgroup, in-
dependently of lymph node status or proximal, possiblyco-deleted 11q22 genes. This indicates a specific role for
YAP1 in predicting outcome in this subgroup. Absent
YAP1 protein expression was shown to be linked to an
impaired tamoxifen response in a randomised patient ma-
terial and in vitro experiments of YAP1 downregulation
resulted in decreased sensitivity to tamoxifen, together
with an increase in ER and PgR protein levels. Further re-
search is warranted to elucidate the exact mechanism on
YAP1 mediating endocrine resistance and its possible use
as a marker in predicting response to tamoxifen.Additional files
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